TNF and COVID-19: IL-6 is a pivotal cytokine and has attracted high levels of interest, and antibodies that block the IL-6 receptor (Tocilizumab and Sarilumab) are currently under phase 2/3 clinical trials for the potential treatment of COVID-19.3,4 Fewer agents dealing with TNF-blocking antibodies such as Adalimumab, Etanercept, and Golimumab have been recommended now in severe COVID-19 illness.3,4